Overexpressing: Webster's Facts and Phrases
Nonfiction Usage Patent UsageA Modified Yeast Consuming L-Arabinose: Patented by Eckhard Boles and Jessica Becker on May 7, 2003. Abstract: The present invention relates to a method for producing a L-arabinose utilizing yeast stain for the production ethanol, whereby a yeast strain is modified by introducing and expressing araAgene (L-arabinose isomerase), araB gene (L-ribulokinase D121-N) and araD gene (L-ribulose-5-P 4-epimerase) and carrying additional mutations in its genome or overexpressing a TAL1 (transaldolase) gene, enabling it to consume L-arabinose, to use it as the only carbon source, and to produce ethanol, as well as a method for producing ethanol using such a modified strain.Androgen Receptor Overexpressing Skeletal Myoblasts: Patented by Lydia C. Pan and Xiao-Ning Wang on February 17, 2003. Abstract: This invention relates to mammalian skeletal myoblasts that overexpress the androgen receptor and screening methods for identifying and characterizing androgen receptor modulators.Antibody-induced apoptosis: Patented by Tsutomu Arakawa and Yoshiko Kita on December 5, 1995. Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to tag Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Apoptosis Induced by Monoclonal Antibody Anti-Her2: Patented by Tsutomu Arakawa and Yoshiko A. Kita on December 4, 1996. Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to tag Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Caudal Protein Recognizing E2f Promoter, Transformants of Overexpressing Caudal, and Use Thereof: Patented by Mi-Sun Hwang, Na-Hyun Choi, Eun-Jin Oh, Jae-Hong Park and Won-Jae Lee on May 30, 2003. Abstract: The present invention relates to a Caudal protein recognizing an E2F promoter, transformants for overexpressing the Caudal protein, and drug screening using the same. Particularly, the Caudal protein overexpressing transformants of the present invention exhibit abnormal proliferation and differentiation, such that they can be used for drug screening.Compositions and methods for reducing radiation and drug resistance in cells: Patented by Esther H. Chang and Kathleen F. Pirollo on December 6, 1997. Abstract: Provided are antisense oligonucleotides directed against the raf-1 gene, Ha-ras gene and HER-2 gene, components of a signal transduction pathway involving oncogenes and their normal counterparts and leading to the phenotype of cellular radioresistance. Administration of these antisense oligonucleotides is shown to reverse the radioresistance phenotype in cells overexpressing HER-2 or a mutant form of Ha-ras. Methods and compositions for reversing radiation resistance among other conditions involving these genes are disclosed.CPC gene for regulating initiation of root hair formation for arabidopsis (thaliana) and transgenic (arabidopsis), plant overexpressing the CPC gene: Patented by Takuji Wada and Kiyotaka Okada on March 1, 1997. Abstract: Disclosed are a CPC gene coding for the amino acid sequence of SEQ ID NO:1 or an amino acid sequence substantially identical with the amino acid sequence of SEQ ID NO:1 and plants having said gene introduced into them. Novel plants with an increased number of root hairs can be obtained by use of said gene.Cytokinin Receptor Ahk3 Involved in Senescence Regulation of Plant and Use Thereof: Patented by Hong-Gil Nam, Hyo-Jung Kim, Hye-Ryun Woo and In-Chul Lee on June 11, 2004. Abstract: The present application relates to Cytokinin receptor AHK3 which is involoved in regulating senescence of a plant and its use.
What people are saying - Write a review
We haven't found any reviews in the usual places.